Please login to the form below

Not currently logged in

Novella Clinical appoints Dr Chris Smyth to head European and Asian operations

He joins the Quintiles company from fellow CRO INC Research

Novella Clinical Quintiles Dr Chris SmythNovella Clinical has appointed Dr Chris Smyth as managing director for its European and Asian operations.  

Dr Smyth joins the Quintiles-owned contract research organisation from INC Research, where he most recently served as senior vice president of clinical development in that CRO's oncology division.  

He has more than 20 years research and development experience in the pharmaceutical industry, during which time he has led CROs and biopharmaceutical companies in both Europe and the US.  

Novella Clinical's chief operating officer Rob King said: "We are fortunate to have someone as experienced as Dr Smyth guiding our team and business objectives in Europe and Asia.  

"His depth of international leadership and oncology operations expertise will prove to be an invaluable resource as we continue to expand our services into new markets."

In his new role Dr Smyth will be based in Novella's European headquarters in Stevenage, England and he succeeds Elizabeth Edwards, who will now serve as executive vice president of global operations, overseeing Novella's clinical monitoring division.

17th March 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...